Expertise in
40
conditions

Dr. Harry E. Sarles

Gastroenterology
Office
3144 Horizon Rd Ste 210, 
Rockwall, TX 
Accepting New Patients
47 Years of Experience
Expertise in
40
conditions
Office
3144 Horizon Rd Ste 210, 
Rockwall, TX 

Overview

Harry Sarles is a Gastroenterologist practicing medicine in Rockwall, Texas. He has been practicing medicine for over 47 years.

Dr. Sarles is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Familial Adenomatous Polyposis, Portal Hypertension, Childhood Volvulus, Ulcerative Colitis, and Gastrectomy.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 10 clinical trials. Dr. Sarles is currently accepting new patients.

Graduate Year

1979

Specialties

Gastroenterology

Licenses

Internal Medicine in TX

Hospital Affiliations

Texas Health Presbyterian Hospital Rockwall
Hunt Regional Medical Center

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Office
3144 Horizon Rd Ste 210, Rockwall, TX 75032

Additional Areas of Focus

Dr. Sarles has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Completed
Publish Date: August 19, 2026
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
AIDA: A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Clinical Efficacy and Safety of Artificial Intelligence (AI) Detection of Adenomas (AIDA) With Standard High Definition With Light in Screening Colonoscopy
AIDA: A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Clinical Efficacy and Safety of Artificial Intelligence (AI) Detection of Adenomas (AIDA) With Standard High Definition With Light in Screening Colonoscopy
Enrollment Status: Unknown
Publish Date: March 19, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

3 Total Publications

Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease.
Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease.
Journal: Journal of gastrointestinal and liver diseases : JGLD
Published: July 28, 2025
Similar Doctors
Expertise in
29
conditions
Dr. Marlyn J. Mayo
Gastroenterology
Expertise in
29
conditions
Dr. Marlyn J. Mayo
Gastroenterology
Referral may be required

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (23.9 miles away)
214-645-8600
Languages Spoken:
English
See accepted insurances

Marlyn Mayo is a Gastroenterologist practicing medicine in Dallas, Texas. Dr. Mayo is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Primary Biliary Cholangitis, Cholestasis, Cholangitis, Cirrhosis, and Liver Transplant.

Expertise in
42
conditions
Dr. Paul R. Tarnasky
Gastroenterology
Expertise in
42
conditions
Dr. Paul R. Tarnasky
Gastroenterology
Referral may be required
Before you request

Physician Associates Of Southwest Dallas

122 W Colorado Blvd, 
Dallas, TX 
 (23.8 miles away)
214-947-6700
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Paul Tarnasky is a Gastroenterologist practicing medicine in Dallas, Texas. Dr. Tarnasky is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Hereditary Pancreatitis, Acute Pancreatitis, Pancreas Divisum, Endoscopy, and Gastric Bypass. Dr. Tarnasky is board certified in Gastroenterology- American Board Of Internal Medicine, Gastroenterology- American Board Of Internal Med, and Gastroenterology- American Board Of Internal Med/Gastroenterology. Dr. Tarnasky is currently accepting new patients.

Expertise in
11
conditions
Dr. Stuart J. Spechler
Gastroenterology
Expertise in
11
conditions
Dr. Stuart J. Spechler
Gastroenterology
Referral may be required

Select Specialty Hospital-Dallas Downtown

3500 Gaston Ave, 
Dallas, TX 
 (20.8 miles away)
214-865-2241
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stuart Spechler is a Gastroenterologist practicing medicine in Dallas, Texas. Dr. Spechler is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Barrett Esophagus, Esophagitis, Endoscopy, and Colonoscopy.

Frequently Asked Questions about Dr. Harry E. Sarles

How do I make an appointment with Dr. Harry E. Sarles?

You can book an appointment with Dr. Harry E. Sarles by calling their office at 214-689-5960. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Harry E. Sarles a top-rated expert for Familial Adenomatous Polyposis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Harry E. Sarles is classified as an Distinguished expert for Familial Adenomatous Polyposis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Harry E. Sarles specialize in?

While Dr. Harry E. Sarles is a Gastroenterology, they have specific expertise in Familial Adenomatous Polyposis, Portal Hypertension, and Childhood Volvulus. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Harry E. Sarles participate in research or clinical trials?

Yes. Dr. Harry E. Sarles has published 3 articles and abstracts on conditions like Familial Adenomatous Polyposis. You can view a list of Dr. Harry E. Sarles's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Harry E. Sarles accept my insurance?

Dr. Harry E. Sarles accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 214-689-5960 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sarles's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 26 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile